Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ZL-1503

Small molecule

ZZai Lab (Shanghai) Co., Ltd.

0

Indications

2

Total Trials

2

Active Trials

0

Competitors

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Study completion

NCT07658482

Phase 1Recruiting

Atopic Dermatitis (AD)

NCT07235384

Clinical

Trials by Indication[1]

Atopic Dermatitis (AD)1 trial

A Phase 1/1b Randomized, Double Blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis (AD)

Recruiting·ZZai Lab (Shanghai) Co., Ltd.·Phase 1·NCT07235384·84 enrolled

Unspecified1 trial

A Phase 1, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-1503 Following a Single Dose of Subcutaneous or Intravenous Administration in Healthy Volunteers.

Not yet recruiting·ZZai Lab (Shanghai) Co., Ltd.·Phase 1·NCT07658482·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ZL-1503. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZL-1503 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
SEC EDGAR — Zai Lab (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: ZZai Lab (Shanghai) Co., Ltd.

Related News